Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$231.52 +0.4%	$214.12	$163.81 ▼ $244.81	$408.95B	0.51	6.48 million shs	2.77 million shs
LLY Eli Lilly and Company	$838.57 -2.0%	$740.99	$623.78 ▼ $937.00	$794.23B	0.47	4.09 million shs	1.70 million shs
REGN Regeneron Pharmaceuticals	$560.52 -1.6%	$573.83	$476.49 ▼ $1,024.36	$60.01B	0.31	1.10 million shs	486,636 shs
SNY Sanofi	$48.27 -1.1%	$48.25	$44.62 ▼ $60.12	$118.58B	0.51	2.74 million shs	1.13 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.10%	-2.51%	+9.77%	+20.13%	+18.68%
LLY Eli Lilly and Company	+1.05%	+4.11%	+13.92%	+7.70%	-7.12%
REGN Regeneron Pharmaceuticals	+1.07%	-5.02%	+2.40%	+0.38%	-43.70%
SNY Sanofi	+0.04%	-2.63%	+2.89%	+0.43%	-11.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$231.52 +0.4%	$214.12	$163.81 ▼ $244.81	$408.95B	0.51	6.48 million shs	2.77 million shs
LLY Eli Lilly and Company	$838.57 -2.0%	$740.99	$623.78 ▼ $937.00	$794.23B	0.47	4.09 million shs	1.70 million shs
REGN Regeneron Pharmaceuticals	$560.52 -1.6%	$573.83	$476.49 ▼ $1,024.36	$60.01B	0.31	1.10 million shs	486,636 shs
SNY Sanofi	$48.27 -1.1%	$48.25	$44.62 ▼ $60.12	$118.58B	0.51	2.74 million shs	1.13 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.10%	-2.51%	+9.77%	+20.13%	+18.68%
LLY Eli Lilly and Company	+1.05%	+4.11%	+13.92%	+7.70%	-7.12%
REGN Regeneron Pharmaceuticals	+1.07%	-5.02%	+2.40%	+0.38%	-43.70%
SNY Sanofi	+0.04%	-2.63%	+2.89%	+0.43%	-11.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.79	Moderate Buy	$231.90	0.17% Upside
LLY Eli Lilly and Company	2.64	Moderate Buy	$948.56	13.12% Upside
REGN Regeneron Pharmaceuticals	2.79	Moderate Buy	$817.67	45.88% Upside
SNY Sanofi	3.00	Buy	$62.67	29.83% Upside

Current Analyst Ratings Breakdown

Latest ABBV, LLY, SNY, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/10/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$231.00 ➝ $284.00
10/10/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$761.00 ➝ $756.00
10/9/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$925.00
10/9/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$250.00
10/8/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$875.00 ➝ $948.00
10/8/2025	ABBV AbbVie	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/8/2025	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
10/8/2025	REGN Regeneron Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/8/2025	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/3/2025	ABBV AbbVie	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$251.00
10/3/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,028.00 ➝ $1,023.00

(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	7.26	$14.95 per share	15.49	$1.90 per share	121.85
LLY Eli Lilly and Company	$45.04B	17.62	$14.11 per share	59.41	$15.03 per share	55.79
REGN Regeneron Pharmaceuticals	$14.20B	4.18	$45.42 per share	12.34	$268.50 per share	2.09
SNY Sanofi	$44.46B	2.67	$5.27 per share	9.16	$33.20 per share	1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	110.24	16.56	1.35	6.45%	699.66%	13.64%	10/31/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	54.85	26.95	1.18	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.68	14.27	14.74	1.81	31.37%	15.06%	11.77%	10/28/2025 (Estimated)
SNY Sanofi	$6.02B	$4.16	11.61	10.16	1.19	21.47%	16.86%	9.63%	10/24/2025 (Estimated)

Latest ABBV, LLY, SNY, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/31/2025	Q3 2025	ABBV AbbVie	$3.26	N/A	N/A	N/A	$15.58 billion	N/A
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
10/28/2025	Q3 2025	REGN Regeneron Pharmaceuticals	$9.73	N/A	N/A	N/A	$3.57 billion	N/A
10/24/2025	Q3 2025	SNY Sanofi	$1.65	N/A	N/A	N/A	$12.62 billion	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.43	$12.89	+$4.46	$12.81	$3.30 billion	$3.68 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/31/2025	Q2 2025	SNY Sanofi	$0.96	$0.90	-$0.06	$1.84	$9.91 billion	$11.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	2.83%	N/A	312.38%	53 Years
LLY Eli Lilly and Company	$6.00	0.72%	N/A	39.22%	11 Years
REGN Regeneron Pharmaceuticals	$3.52	0.63%	N/A	8.87%	N/A
SNY Sanofi	$1.60	3.31%	N/A	38.46%	N/A

Latest ABBV, LLY, SNY, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/5/2025	ABBV AbbVie	quarterly	$1.64	3.08%	10/15/2025	10/15/2025	11/14/2025
8/1/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	8/18/2025	8/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
LLY Eli Lilly and Company	1.86	1.28	1.00
REGN Regeneron Pharmaceuticals	0.09	4.60	3.72
SNY Sanofi	0.19	1.27	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
REGN Regeneron Pharmaceuticals	83.31%
SNY Sanofi	14.04%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
LLY Eli Lilly and Company	0.13%
REGN Regeneron Pharmaceuticals	7.02%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	105.99 million	98.55 million	Optionable
SNY Sanofi	82,878	2.46 billion	2.43 billion	Optionable

ABBV, LLY, SNY, and REGN Headlines

Recent News About These Companies

Leerink Partnrs Issues Negative Forecast for Sanofi Earnings

October 10 at 7:27 AM | marketbeat.com

Callan Family Office LLC Boosts Stock Holdings in Sanofi $SNY

October 10 at 5:23 AM | marketbeat.com

Sanofi (NASDAQ:SNY) Receives $62.67 Average Target Price from Brokerages

October 10 at 2:58 AM | americanbankingnews.com

Sanofi (NASDAQ:SNY) Earns "Hold (C)" Rating from Weiss Ratings

October 9 at 3:51 AM | marketbeat.com

Sanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

October 8 at 12:36 AM | msn.com

Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy

October 8 at 12:36 AM | msn.com

BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform

October 8 at 8:18 AM | businesswire.com

OLD National Bancorp IN Decreases Stock Position in Sanofi $SNY

October 8 at 4:07 AM | marketbeat.com

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

October 8 at 2:00 AM | globenewswire.com

Novavax’s Nuvaxovid EU approval triggers $25M milestone payment from Sanofi

October 7 at 12:24 PM | msn.com

Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU

October 7 at 12:24 PM | msn.com

Merit Financial Group LLC Has $4.37 Million Stock Holdings in Sanofi $SNY

October 7 at 4:34 AM | marketbeat.com

Sanofi (NASDAQ:SNY) Given Average Rating of "Buy" by Brokerages

October 7 at 2:14 AM | marketbeat.com

DAVENPORT & Co LLC Has $101.77 Million Stock Holdings in Sanofi $SNY

October 6, 2025 | marketbeat.com

Sanofi (SNY) Invests $625 Million in Sanofi Ventures

October 5, 2025 | msn.com

UBS Reaffirms Their Buy Rating on Sanofi (SNYNF)

October 4, 2025 | theglobeandmail.com

Hilltop National Bank Makes New $662,000 Investment in Sanofi $SNY

October 4, 2025 | marketbeat.com

Patriot Financial Group Insurance Agency LLC Has $1.45 Million Stock Position in Sanofi $SNY

October 4, 2025 | marketbeat.com

Leerink Partnrs Has Negative Outlook for Sanofi Q4 Earnings

October 4, 2025 | americanbankingnews.com

Matauro LLC Invests $1.85 Million in Sanofi $SNY

October 3, 2025 | marketbeat.com

Sanofi $SNY Shares Bought by Janney Montgomery Scott LLC

October 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABBV, LLY, SNY, and REGN Company Descriptions

AbbVie NYSE:ABBV

$231.52 +0.83 (+0.36%)

As of 01:35 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$838.57 -16.78 (-1.96%)

As of 01:35 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Regeneron Pharmaceuticals NASDAQ:REGN

$560.52 -9.38 (-1.65%)

As of 01:35 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sanofi NASDAQ:SNY

$48.27 -0.55 (-1.13%)

As of 01:35 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABBV, LLY, SNY, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABBV, LLY, SNY, and REGN Earnings

Compare Dividends

Latest ABBV, LLY, SNY, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABBV, LLY, SNY, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABBV, LLY, SNY, and REGN Company Descriptions

AbbVie NYSE:ABBV

Eli Lilly and Company NYSE:LLY

Regeneron Pharmaceuticals NASDAQ:REGN

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools